Medicare Coverage for BPH and Overactive Bladder: Drugs, Surgery, and Procedures

Benign prostatic hyperplasia (BPH) affects roughly half of men in their sixties and more than 80 percent of men in their eighties. Overactive bladder (OAB) is even more pervasive, affecting an estimated 33 million Americans — both men and women — with urgency, frequency, and unintended urine loss that disrupts daily life. Both conditions peak in the Medicare-age population, and both generate substantial treatment costs: expensive brand-name medications, outpatient procedures ranging from $3,000 to $15,000, and in some cases surgically implanted devices.

Medicare covers the full spectrum of BPH and OAB treatment — but the rules are counterintuitive in places that matter financially. Some drugs that are cheap generics are well-covered; others cost $300 per month under Part D. A newer drug for OAB avoids a serious cognitive side effect but may not be covered by your specific plan. And several minimally invasive BPH procedures that patients often assume are experimental are in fact fully covered by Medicare. This guide explains what each part of Medicare pays, what patients typically owe, and where the key surprises are.

BPH vs. OAB vs. Prostatitis: What Medicare Sees Differently

The first distinction matters for diagnosis and coverage:

BPH (benign prostatic hyperplasia) is an enlarged prostate gland that obstructs urine outflow. It causes slow stream, hesitancy, incomplete emptying, nocturia, and urgency. BPH is not cancer and does not increase cancer risk, but it shares some symptoms with prostate cancer and can elevate PSA. It affects only men. See Medicare coverage for prostate cancer for how coverage diverges when cancer is suspected.

OAB (overactive bladder) is a condition of the bladder muscle itself — the detrusor contracts involuntarily, creating sudden, intense urge to urinate. OAB causes urgency, frequency (typically 8+ voids per day), and often urgency incontinence. OAB can occur independently of BPH and affects both sexes; many men have both simultaneously.

Prostatitis (prostate inflammation or infection) is a separate condition with different treatments (antibiotics for bacterial forms) and different billing codes — covered under Part B as diagnostic and treatment services, similar to other infections.

Medicare covers all three, but the drugs and procedures reimbursed are specific to each diagnosis.

Part B: Diagnostic Workup for BPH and OAB

Before treatment, Medicare Part B covers the diagnostic workup:

For BPH:

• PSA blood test: Covered at 100 percent as a clinical laboratory test (no coinsurance, no deductible) — used to distinguish BPH from prostate cancer before invasive evaluation
• Urinalysis and urine culture: Covered as lab tests, zero cost-sharing
• Post-void residual (PVR) ultrasound: Covered under Part B; you owe 20 percent of the Medicare-approved amount after the $257 Part B deductible (2026)
• Uroflowmetry: Measures urine flow rate; covered under Part B as an outpatient diagnostic test
• Transrectal ultrasound (TRUS): Covered when ordered for prostate evaluation

For OAB:

• Urodynamic testing: Measures bladder pressure, capacity, and leakage under controlled conditions; covered under Part B; commonly requires prior authorization on Medicare Advantage plans
• Cystoscopy: Direct visualization of the bladder and urethra; covered under Part B; typically performed in the urologist’s office or a hospital outpatient department

What you pay: Under original Medicare without a supplement, you owe 20 percent of the Medicare-approved amount for all Part B services after the annual deductible. Medigap Plan G covers that 20 percent, reducing diagnostic costs to essentially zero beyond the deductible.

Part D Coverage for BPH Medications

The most common BPH medications are covered under Medicare Part D drug plans, but costs vary widely by drug class and whether generics are available.

Alpha Blockers: Cheap and Well-Covered

Alpha blockers relax the smooth muscle of the prostate and bladder neck, improving urine flow quickly. Generic versions are available for all commonly prescribed alpha blockers, making them among the most affordable BPH medications:

• Tamsulosin (Flomax): Generic widely available; typically Tier 1 or Tier 2 on most formularies — expect $5–$15 per month out of pocket
• Terazosin and doxazosin: Older generics; even cheaper; Tier 1 on virtually all plans; note that terazosin and doxazosin can cause significant blood pressure drops (orthostatic hypotension) and require slow dose titration
• Alfuzosin (Uroxatral): Generic available; typically Tier 2–3
• Silodosin (Rapaflo): No generic; brand only; can land on Tier 3 or higher, pushing costs to $100–$200 per month depending on your plan

The practical takeaway: if your urologist prescribes tamsulosin, you’re looking at a $5-per-month drug under most Part D plans. If you’re on silodosin, it’s worth calling your plan to ask whether a prior authorization or step therapy through tamsulosin first would lower your cost.

5-Alpha Reductase Inhibitors (5-ARIs): Generics Now Available

5-ARIs shrink the prostate over several months and are most useful for men with significantly enlarged prostates (>40g). They are often combined with alpha blockers for better symptom control.

• Finasteride (Proscar): Generic widely available; Tier 1–2; ~$5–$20 per month. Note: finasteride is also sold at lower dose as Propecia for hair loss — Part D does not cover finasteride for hair loss (cosmetic), but does cover it when prescribed for BPH (medical). The distinction is the indication on the prescription.
• Dutasteride (Avodart): Generic now available; typically Tier 2–3; ~$15–$40 per month with generic
• Combination dutasteride/tamsulosin (Jalyn): Brand only; more expensive; most plans will require trying the generics separately before covering Jalyn

Tadalafil for BPH: A Coverage Surprise

Tadalafil (Cialis) received FDA approval for BPH at 5 mg daily in 2011 — a separate indication from its use in erectile dysfunction. This matters for Medicare Part D because:

Medicare Part D explicitly excludes coverage for drugs used to treat sexual dysfunction (erectile dysfunction). However, tadalafil prescribed specifically for BPH is a different FDA indication. Many Part D plans do cover generic tadalafil when the prescription is written for BPH, because the exclusion applies to the sexual dysfunction indication, not the BPH indication.

The practical outcome varies by plan. Generic tadalafil is typically Tier 1–2 when covered for BPH, costing $10–$30 per month. If your plan denies it, your doctor can submit a formulary exception request citing the BPH indication (ICD-10 N40.0/N40.1), not ED.

Part D Coverage for OAB Medications

OAB medications split into two classes with very different Part D cost profiles and a clinically important safety distinction.

Anticholinergics: Inexpensive but with Cognitive Risk

Anticholinergic medications block bladder muscle contractions and reduce urgency. Generics exist for most, keeping costs low:

• Oxybutynin (Ditropan): Oldest and cheapest; generic ~$5/month; also available as a generic patch (oxybutynin transdermal)
• Tolterodine (Detrol LA): Generic available; Tier 2–3; ~$15–$40 per month
• Trospium: Generic available; typically Tier 2
• Solifenacin (VESIcare): Now has generic; reduced cost vs. brand ($15–$50 vs. $200+)
• Darifenacin (Enablex): Generic available
• Fesoterodine (Toviaz): Brand; limited generic; $150–$250 per month without good plan coverage

The critical concern: Multiple studies — including a large 2021 JAMA Internal Medicine analysis — link cumulative anticholinergic use to increased dementia risk in older adults. The American Geriatrics Society’s Beers Criteria lists most bladder anticholinergics as potentially inappropriate for adults over 65. This is not a reason to avoid them entirely, but it is a reason for patients over 70 to discuss the newer beta-3 class with their physician — and for Medicare coverage to matter more, since the safer alternatives are significantly more expensive.

Beta-3 Agonists: Safer for Older Adults, Expensive Under Part D

Beta-3 agonists relax the bladder detrusor muscle through a different mechanism that does not carry the anticholinergic cognitive burden:

• Mirabegron (Myrbetriq): No generic; brand only; typically Tier 3–4 on Part D formularies; cost ranges from $200–$400 per month depending on your plan. The $2,100 annual out-of-pocket cap under Part D (as of 2024) limits total drug costs for the year, but even with the cap, Myrbetriq can be a major portion of your annual drug spend before you hit the threshold.
• Vibegron (Gemtesa): No generic; brand; similar price tier to Myrbetriq; newer (FDA approved 2020)

If you or a family member is concerned about anticholinergic cognitive risk and needs Myrbetriq, verify your specific plan’s formulary before assuming it’s unaffordable. Some plans place it on Tier 3 with a reasonable fixed copay. The Extra Help (LIS) program also reduces cost-sharing substantially for qualifying low-income beneficiaries — see Medicare Savings Programs.

Part B: BPH Surgical and Minimally Invasive Procedures

When medications don’t control BPH symptoms, Medicare Part B covers a range of procedures — including minimally invasive outpatient options that many patients and even some physicians are unaware Medicare pays for.

TURP (Transurethral Resection of the Prostate)

TURP is the traditional gold standard for BPH surgery: a resectoscope removes prostate tissue through the urethra without external incisions. It is the most studied and longest-tracked BPH procedure.

• Classification: Almost always performed as outpatient or observation under Part B
• Cost without supplemental coverage: 20 percent of the Medicare-approved facility and professional fees; a typical TURP totaling $10,000–$15,000 in charges leaves the patient owing $2,000–$3,000 in uncovered coinsurance
• Medigap Plan G: Covers the 20 percent coinsurance; patient owes only the $257 annual deductible if already met

Laser Procedures: GreenLight PVP and HoLEP

Laser procedures (GreenLight photovaporization, HoLEP holmium enucleation, ThuLEP thulium laser enucleation) are covered under Part B as outpatient procedures and are billed similarly to TURP. HoLEP in particular is increasingly preferred for large prostates because it offers TURP-equivalent outcomes with lower retreatment rates. Medicare coverage does not require you to start with TURP and fail before getting a laser procedure.

Rezūm Water Vapor Therapy

Rezūm uses steam injected directly into prostate tissue, causing targeted cell death and prostate shrinkage over 2–3 months. It is performed in a urologist’s office or outpatient facility in a single session under local anesthesia.

• Medicare coverage: Covered under Part B; CMS assigned a specific payment category (C9766 transitional pass-through code, subsequently incorporated into standard APC payment)
• Who is eligible: Men with prostate volume 30–80 mL; symptomatic BPH inadequately controlled by medications
• Cost: 20 percent coinsurance of the Medicare-approved amount; Medigap Plan G covers the coinsurance

UroLift (Prostatic Urethral Lift)

UroLift is an in-office procedure that places small permanent implants to hold the enlarged prostate lobes apart, improving urine flow without removing tissue or creating thermal damage. FDA approved in 2013 and supported by Medicare national coverage.

• Medicare coverage: Covered under Part B as an outpatient procedure
• Advantage: Preserves ejaculatory function — relevant for sexually active men (Rezūm and TURP carry higher rates of retrograde ejaculation)
• Limitation: Less effective for very large prostates or a prominent median lobe

For both Rezūm and UroLift, Medicare Advantage plans typically require prior authorization. Confirm in-network provider status before booking the procedure, as a Medicare Advantage patient who sees an out-of-network facility may face much higher out-of-pocket costs.

Part B: OAB Procedures

When medications fail for OAB, Medicare Part B covers two procedural options:

OnabotulinumtoxinA (Botox) for OAB

Botox injections into the bladder wall (intradetrusor injections) relax the overactive detrusor muscle. The effect lasts 6–12 months, after which the injection can be repeated.

• Coverage: Covered under Part B as a physician-administered drug (J0585 — onabotulinumtoxinA per unit); the procedure (CPT 52287) is also a Part B outpatient service
• Why Part B, not Part D: Because the drug is administered in a physician’s office or outpatient facility, it falls under Part B physician-administered drug rules, not Part D retail pharmacy coverage. This is the same Part B vs. Part D split that applies to infused biologics and IV chemotherapy.
• Cost without supplemental coverage: 20 percent of the Medicare-approved amount; total procedure costs commonly run $1,500–$2,500, leaving the patient owing $300–$500 per injection under original Medicare
• With Medigap Plan G: Coinsurance covered; only the annual deductible applies

Sacral Neuromodulation (InterStim, Axonics)

Sacral neuromodulation (SNM) involves surgically implanting a small pulse generator near the sacral nerve roots to modulate bladder signaling. Two stages are involved: a trial period with an external device, then permanent implant if the trial shows benefit.

• Coverage: Medicare Part B covers both the implantation procedure (CPT 64590, 64561) and the device (HCPCS for the implantable device)
• Indication: Covered for refractory urge incontinence, urgency-frequency, and urinary retention that has not responded to medications and behavioral therapy
• Devices: Medtronic InterStim Micro and InterStim X; Axonics Sacral Neuromodulation System; both are Medicare-approved
• Cost scale: Device and implant procedure can total $20,000–$30,000; patient owes 20 percent under original Medicare (~$4,000–$6,000); Medigap Plan G eliminates the coinsurance exposure

Inpatient vs. Outpatient: What the 2-Midnight Rule Means for BPH Surgery

Whether BPH surgery is billed under Part A (inpatient) or Part B (outpatient) affects what you pay and whether the stay qualifies for skilled nursing facility (SNF) coverage:

• Part B (outpatient): You pay 20 percent of the Medicare-approved amount; the stay does not count as a qualifying 3-night inpatient stay for SNF coverage
• Part A (inpatient): You pay the $1,736 Part A deductible per benefit period; the stay does count toward SNF qualification if complications require post-acute care

For TURP and laser procedures, most patients are discharged same-day or the next day — meaning inpatient classification is unusual. Urinary retention requiring catheterization or complications like bleeding may push toward inpatient. If the hospital places you under “observation” rather than inpatient admission, clarify your status immediately, as observation is a Part B service and does not satisfy the 3-day SNF requirement. See what is Medicare Part B for detail on the observation vs. inpatient distinction.

Cost Summary

For overall plan cost comparisons including Medigap vs. Medicare Advantage, see Medicare Supplement vs. Advantage costs.

7-Step Planning Guide

1. Get a diagnosis, not just a prescription: Urodynamic testing distinguishes BPH from OAB from mixed etiology — the treatment pathways are different, and a urologist’s workup clarifies which Part B diagnostics you need.
2. Start with generic alpha blockers for BPH: Tamsulosin is as effective as brand alternatives for most patients and costs a fraction of the monthly price. Try Tier 1–2 generics first before pursuing expensive combination drugs.
3. Ask about OAB drug safety at your age: If you’re over 70, ask your physician whether a beta-3 agonist (Myrbetriq or Gemtesa) is a better choice than an anticholinergic given the Beers Criteria cognitive-risk concern — then check your Part D plan’s formulary to determine your actual copay.
4. Check tadalafil coverage for BPH separately: If your doctor recommends tadalafil for BPH, verify that the prescription specifies the BPH indication (N40.x), not ED. Many plans cover generic tadalafil for BPH that they wouldn’t cover for sexual dysfunction.
5. Know your minimally invasive options before defaulting to TURP: Rezūm and UroLift are Medicare-covered procedures that offer recovery advantages over TURP for appropriately sized prostates. If your urologist hasn’t mentioned them, ask whether you’re a candidate.
6. Request prior authorization documents for procedures under Medicare Advantage: Rezūm, UroLift, urodynamic testing, and sacral neuromodulation all commonly require prior authorization. Confirm network status and authorization before scheduling to avoid surprise bills.
7. Compare annual drug costs across plans using Medicare’s Plan Finder: If you’re taking Myrbetriq or a brand OAB medication, run your drug list through the Medicare Plan Finder each fall during open enrollment — formulary placement changes year to year and a plan switch can save hundreds of dollars annually.

Frequently Asked Questions

Does Medicare cover Flomax (tamsulosin)? Yes. Generic tamsulosin is covered under Part D at Tier 1 or Tier 2 on most formularies — typically $5–$15 per month out of pocket.

Does Medicare cover Myrbetriq (mirabegron)? Myrbetriq is covered under Part D but is typically a Tier 3 or Tier 4 drug with higher cost-sharing — often $200–$400 per month depending on your plan. Check your specific plan’s formulary. The annual $2,100 out-of-pocket cap under Part D limits your total drug spend for the year.

Does Medicare cover Rezūm and UroLift? Yes, both are covered under Part B as outpatient procedures. Under original Medicare, you pay 20 percent coinsurance. Medigap Plan G covers that coinsurance. Medicare Advantage requires prior authorization — confirm coverage before scheduling.

Does Medicare cover Botox injections for overactive bladder? Yes. OnabotulinumtoxinA (Botox) for OAB is covered under Part B as a physician-administered drug — not under Part D. You pay 20 percent of the approved amount; Medigap Plan G covers that coinsurance.

Can Medicare cover tadalafil (Cialis) for BPH even though Part D excludes ED drugs? Often yes — when the prescription is written specifically for BPH (not ED), many Part D plans do cover generic tadalafil because the Part D sexual dysfunction exclusion applies to the ED indication, not the BPH indication. The prescription must clearly state the BPH diagnosis.

My father has BPH and also has early CKD — does that change anything? Yes. Severe or longstanding BPH can cause urinary obstruction that damages kidney function (obstructive uropathy). If your father has both conditions, his urologist and nephrologist should coordinate care. Medicare covers both specialties under Part B. See Medicare coverage for chronic kidney disease for how Medicare manages kidney disease alongside other conditions.